Edition:
United Kingdom

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Capital Market

1.69USD
18 Dec 2018
Change (% chg)

$-0.06 (-3.43%)
Prev Close
$1.75
Open
$1.75
Day's High
$1.81
Day's Low
$1.64
Volume
26,158
Avg. Vol
32,789
52-wk High
$24.50
52-wk Low
$1.64

Latest Key Developments (Source: Significant Developments)

Invivo Therapeutics Holdings Says Received Notification Co Was Not In Compliance With Nasdaq Listing Rule On Aug.15
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS HOLDINGS - ON AUG.15, RECEIVED NOTIFICATION CO WAS NOT IN COMPLIANCE WITH NASDAQ LISTING RULE 5550(B)(1).INVIVO THERAPEUTICS HOLDINGS CORP - EXPECTS TO SUBMIT A PLAN TO REGAIN COMPLIANCE WITH CONTINUED LISTING REQUIREMENTS.  Full Article

InVivo Therapeutics Announces Latest Results From INSPIRE
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD.INVIVO THERAPEUTICS HOLDINGS - 19 PATIENTS IMPLANTED WITH NEURO-SPINAL SCAFFOLD;3 PATIENTS DIED WITHIN 2 WEEKS OF IMPLANTATION​ IN STUDY.INVIVO THERAPEUTICS HOLDINGS CORP - ‍16 EVALUABLE PATIENTS HAVE NOW ALL REACHED SIX-MONTH PRIMARY ENDPOINT VISIT IN STUDY​.INVIVO THERAPEUTICS - ‍DOES NOT ANTICIPATE REOPENING ENROLLMENT IN INSPIRE,EXPECTS TO PROVIDE ADDITIONAL CLARITY ON CLINICAL PATH FORWARD IN Q2 2018​.  Full Article

InVivo Therapeutics Announces Executive Management And Board Changes
Monday, 18 Dec 2017 

Dec 18 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES.INVIVO THERAPEUTICS HOLDINGS CORP - ‍RICHARD TOSELLI, NAMED ACTING CHIEF EXECUTIVE OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI REPLACES MARK PERRIN, WHO HAS RESIGNED AS CEO AND CHAIRMAN OF INVIVO'S BOARD OF DIRECTORS​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ANN MERRIFIELD WAS APPOINTED AS CHAIR OF BOARD OF DIRECTORS​.  Full Article

InVivo Therapeutics reports Q3 loss per share $0.28
Monday, 30 Oct 2017 

Oct 30 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics provides business update and reports 2017 third quarter financial results.Q3 adjusted loss per share $0.19 excluding items.Q3 loss per share $0.28.  Full Article